Two multidrug-resistance (ABCB1) gene polymorphisms as prognostic parameters in women with ovarian cancer

Anticancer Research

Volumn 30, Issue 9, 2010, Pages 3487-3491

  Grimm, Christoph ^a   Polterauer, Stephan ^a   Zeillinger, Robert ^a   Tong, Dan ^a   Heinze, Georg ^a   Wolf, Andrea ^a   Natter, Camilla ^a   Reinthaller, Alexander ^a   Hefler, Lukas A ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

ABCB1; Gene; Ovarian cancer; Polymorphism; Prognosis

Indexed keywords

MULTIDRUG RESISTANCE PROTEIN 1; ABCB1 PROTEIN, HUMAN; MULTIDRUG RESISTANCE PROTEIN;

ADULT; ARTICLE; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; DISEASE FREE SURVIVAL; EXON; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; DRUG RESISTANCE; GENETICS; GENOTYPE; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; OVARY TUMOR; PATHOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM;

DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; GENOTYPE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; P-GLYCOPROTEIN; P-GLYCOPROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS;

EID: 77958550731     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Pauli-Magnus C and Kroetz DL: Functional implications of genetic polymorphisms in the multidrug resistance gene MDR1 (ABCB1). Pharm Res 21: 904-913, 2004.
2. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I and Willingham MC: Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84: 7735-7738, 1987.
3. Jekerle V, Klinkhammer W, Scollard DA, Breitbach K, Reilly RM, Piquette-Miller M and Wiese M: In vitro and in vivo evaluation of WK-X-34, a novel inhibitor of P-glycoprotein and BCRP, using radio imaging techniques. Int J Cancer 119: 414-422, 2006.
4. Glazer RI and Rohlff C: Transcriptional regulation of multidrug resistance in breast cancer. Breast Cancer Res Treat 31: 263-271, 1994. (Pubitemid 24323467)
5. Marzolini C, Paus E, Buclin T and Kim RB: Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 75: 13-33, 2004.
6. Zhou SF: Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica 38: 802-832, 2008.
7. Baekelandt MM, Holm R, Nesland JM, Tropé CG and Kristensen GB: P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer. Anticancer Res 20: 1061-1067, 2000.
8. Ng IO, Liu CL, Fan ST and Ng M: Expression of P-glycoprotein in hepatocellular carcinoma. A determinant of chemotherapy response. Am J Clin Pathol 113: 355-363, 2000.
9. Allen JD, Brinkhuis RF, van Deemter L, Wijnholds J and Schinkel AH: Extensive contribution of the multidrug transporters P-glycoprotein and Mrp1 to basal drug resistance. Cancer Res 60: 5761-5766, 2000.
10. Naniwa J, Kigawa J, Kanamori Y, Itamochi H, Oishi T, Shimada M, Shimogai R, Kawaguchi W, Sato S and Terakawa N: Genetic diagnosis for chemosensitivity with drug-resistance genes in epithelial ovarian cancer. Int J Gynecol Cancer 17: 76-82, 2007.
11. Kamazawa S, Kigawa J, Kanamori Y, Itamochi H, Sato S, Iba T and Terakawa N: Multidrug resistance gene-1 is a useful predictor of paclitaxel-based chemotherapy for patients with ovarian cancer. Gynecol Oncol 86: 171-176, 2002. (Pubitemid 34953500)
12. Gréen H, Söderkvist P, Rosenberg P, Horvath G and Peterson C: MDR-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy. Clin Cancer Res 12: 854-859, 2006.
13. Illmer T, Schuler US, Thiede C, Schwarz UI, Kim RB, Gotthard S, Freund D, Schäkel U, Ehninger G and Schaich M: MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukaemia patients. Cancer Res 62: 4955-4962, 2002.
14. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, Taylor A, Xie HG, McKinsey J, Zhou S, Lan LB, Schuetz JD, Schuetz EG and Wilkinson GR: Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 70: 189-199, 2001.
15. Mrozikiewicz PM, Seremak-Mrozikiewicz A, Semczuk A, Landt O, Breborowicz GH and Drews K: The significance of C3435T point mutation of the MDR1 gene in endometrial cancer. Int J Gynecol Cancer 17: 728-731, 2007. (Pubitemid 46743994)
16. Turgut S, Yaren A, Kursunluoglu R and Turgut G: MDR1 C3435T polymorphism in patients with breast cancer. Arch Med Res 38: 539-544, 2007.
17. Tahara T, Arisawa T, Shibata T, Hirata I and Nakano H: Multi-drug resistance 1 polymorphism is associated with reduced risk of gastric cancer in the Japanese population. J Gastroenterol Hepatol 22: 1678-1682, 2007.
18. Kurzawski M, Droździk M, Suchy J, Kurzawski G, Białecka M, Górnik W and Lubiński J: Polymorphism in the P-glycoprotein drug transporter MDR1 gene in colon cancer patients. Eur J Clin Pharmacol 61: 389-394, 2005. (Pubitemid 41569314)
19. Urayama KY, Wiencke JK, Buffler PA, Chokkalingam AP, Metayer C and Wiemels JL: MDR1 gene variants, indoor insecticide exposure, and the risk of childhood acute lymphoblastic leukemia. Cancer Epidemiol Biomarkers Prev 16: 1172-1177, 2007.
20. Kafka A, Sauer G, Jaeger C, Grundmann R, Kreienberg R, Zeillinger R and Deissler H: Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer. Int J Oncol 22: 1117-1121, 2003.
21. Wu X, Gu J, Wu TT, Swisher SG, Liao Z, Correa AM, Liu J, Etzel CJ, Amos CI, Huang M, Chiang SS, Milas L, Hittelman WN and Ajani JA: Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. J Clin Oncol 24: 3789-3798, 2006.
22. Monzo M, Brunet S, Urbano-Ispizua A, Navarro A, Perea G, Esteve J, Artells R, Granell M, Berlanga J, Ribera JM, Bueno J, Llorente A, Guardia R, Tormo M, Torres P, Nomdedéu JF, Montserrat E and Sierra J; CETLAM: Genomic polymorphisms provide prognostic information in intermediate-risk acute myeloblastic leukemia. Blood 107: 4871-4879, 2006.
23. Buda G, Maggini V, Galimberti S, Martino A, Giuliani N, Morabito F, Genestreti G, Iacopino P, Rizzoli V, Barale R, Rossi AM and Petrini M: MDR1 polymorphism influences the outcome of multiple myeloma patients. Br J Haematol 137: 454-456, 2007.
24. Marsh S, King CR, McLeod HL, Paul J, Gifford G and Brown R: ABCB1 2677G>T/A genotype and paclitaxel pharmacogenetics in ovarian cancer. Clin Cancer Res 12: 4127, 2006. (Pubitemid 44078102)
25. Marsh S, Paul J, King CR, Gifford G, McLeod HL and Brown R: Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. J Clin Oncol 25: 4528-4535, 2007.
26. Johnatty SE, Beesley J, Paul J, Fereday S, Spurdle AB, Webb PM, Byth K, Marsh S and McLeod H; AOCS Study Group, Harnett PR, Brown R, DeFazio A and Chenevix-Trench G: ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy. Clin Cancer Res 14: 5594-5601, 2008.
27. Kaye SB: Reversal of drug resistance in ovarian cancer: where do we go from here? J Clin Oncol 26: 2616-2618, 2008.
28. Helleman J, Jansen MP, Span PN, van Staveren IL, Massuger LF, Meijer-van Gelder ME, Sweep FC, Ewing PC, van der Burg ME, Stoter G, Nooter K and Berns EM: Molecular profiling of platinum-resistant ovarian cancer. Int J Cancer 118: 1963-1971, 2006.
29. Jazaeri AA, Awtrey CS, Chandramouli GV, Chuang YE, Khan J, Sotiriou C, Aprelikova O, Yee CJ, Zorn KK, Birrer MJ, Barrett JC and Boyd J: Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers. Clin Cancer Res 11: 6300-6310, 2005.
30. Spentzos D, Levine DA, Kolia S, Otu H, Boyd J, Libermann TA and Cannistra SA: Unique gene expression profile based on pathologic response in epithelial ovarian cancer. J Clin Oncol 23: 7911-7918, 2005.